Plus   Neg

Boston Scientific Updates FY18 Guidance - Quick Facts

Boston Scientific Corp. (BSX) announced, for fiscal 2018, the company now estimates income on a GAAP basis in a range of $0.90 to $0.94 per share (compared to prior guidance of $0.93 to $0.98 per share) and estimates adjusted earnings in a range of $1.37 to $1.41 per share (compared to prior guidance of $1.35 to $1.39 per share).

The company now estimates revenue for the full year 2018 to be in a range of $9.750 to $9.900 billion (compared to prior guidance of $9.650 to $9.800 billion), which versus the prior year period represents a growth range of approximately 8 to 10 percent on a reported basis and growth of approximately 5 to 7 percent on an organic basis excluding the impact of foreign currency fluctuations and contribution of approximately 40 basis points from Symetis.

Boston Scientific reported firs-quarter adjusted earnings per share of $0.33, compared to $0.29 a year ago. Sales were $2.379 billion during the first quarter ended March 31, 2018. This represents growth of 10.1 percent on a reported basis, 6.2 percent on an operational basis and 5.2 percent on an organic basis, compared to the prior year period.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug major Roche Holding AG reported Wednesday higher sales in its first nine months of fiscal 2018, with growth in Pharmaceuticals sales in all regions except Europe. Diagnostics Division also recorded higher sales in all regions. Looking ahead to fiscal 2018, Roche confirmed its outlook for higher results at constant exchange rates. Online-video streaming service Netflix Inc. (NFLX), Tuesday reported a third-quarter profit that surged from last year as revenues increased 34% driven largely by strong subscriber additions. Shares surged nearly 12 percent in the after-hours trading. Netflix added 6.96 million subscribers globally... Despite opposition from the pharmaceutical industry, President Donald Trump's administration has proposed a new rule requiring companies to include the prices for prescription drug and biological products in their television advertisements.
Follow RTT